BCX 7353

Drug Profile

BCX 7353

Alternative Names: BCX7353

Latest Information Update: 21 Mar 2017

Price : $50

At a glance

  • Originator BioCryst Pharmaceuticals
  • Class Skin disorder therapies; Small molecules
  • Mechanism of Action Bradykinin inhibitors; Kallikrein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hereditary angioedema

Most Recent Events

  • 03 Mar 2017 Pharmacokinetics and pharmacodynamics data from preclinical studies in Hereditary angioedema presented at the Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI-2017)
  • 27 Feb 2017 Pharmacokinetics data from a phase I trial in Hereditary angioedema released by BioCryst Pharmaceuticals (BioCryst Pharmaceuticals 10-K, February 2017)
  • 27 Feb 2017 Interim efficacy and adverse event data from the phase II APeX-1 trial in Hereditary angioedema released by BioCryst
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top